Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017
Download this press release (170 KB).
ROSEVILLE, MN (October 12, 2017) —Rebiotix Inc., a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that three posters have been accepted for presentation at the World Congress of Gastroenterology at ACG2017 being held October 13th-18th in Orlando, Florida. The posters will feature new clinical findings from RBX2660 Phase 2 studies, including analyses of microbiome changes in patients who received Rebiotix’s lead drug in its Microbiota Restoration Therapy™ platform. Additionally, researchers will present new Rebiotix-sponsored biomarker research aimed at developing a human Microbiome Health Index (MHI)™.
RBX2660 is currently being evaluated in an international Phase 3 clinical trial for the prevention of recurrent Clostridium difficile infection (C. diff.).
The schedule of presentation is as follows: